Alexion Pharmaceuticals Inc $ 115.07 -3.14 (-2.66%)
ALXN News and Headlines - Alexion Pharmaceuticals Inc
The fund closed its position in Gilead Sciences Inc. (GILD). The trade had an impact of -1.59% on the portfolio.
The company, which develops therapies to treat life-threatening infectious diseases, has a market cap of $74.12 billion and an enterprise value of $79.42 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on
Managed by Jason Kritzer and Samantha Pandolfi, the fund, which is part of Boston-based Eaton Vance, invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.
Although the fund added six new holdings to the portfolio during the three months ended Aug. 31, its most notable trades included an addition to its AbbVie
After establishing a holding in Bellus Health Inc. (BLU) during the second quarter, billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, upped the position by 1,712.12%.
In order to generate superior risk-adjusted returns, the guru's Stamford, Connecticut-based firm invests in a wide range of asset classes worldwide. Its long-short strategy is based on bottom-up research processes focusing on fundamentals and macroeconomic conditions.
According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in 5.87 million shares of the Canadian biotech company on Oct. 22, impacting the equity portfolio by
Cambridge, Massachusetts-based ElevateBio deserves a pat on the back for making a Houston biotech firm the first company in its portfolio last year.
AlloVir Inc. (ALVR) went public in an upsized initial public offering last week, raising $276 million by selling 16.3 million shares at $17. That means that in just a matter of days, the stock has soared more than 70% to $29.40, giving the company a market value of more than $1.8 billion.
AlloVir’s IPO funds will go toward pushing ahead its program aimed at using its allogeneic T cell therapies to treat viral
Four fledgling companies that recently joined the parade of biotechs marching to the initial public offering starting line have met with mixed investor reception.One of the companies is trading above its offering price, two are relatively flat and the fourth has lost value.
Pacing the gainers is Inozyme Pharma Inc. (INZY), which went public at $16 and is up 15% to $18.40. At $19.57 Nurix Therapeutics Inc. (NRIX).is just more than 50 cents above its offering price, as is Annexon Inc. (ANNX), which went public at $17. Dragging the group down is ITeos Therapeutics Inc. (ITOS), down more than 8%
In light of Novavax Inc. (NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (ALXN), Novo Nordisk A/S (NVO), Galapagos NV (GLPG), Regeneron Pharmaceuticals Inc. (REGN) and Vertex Pharmaceuticals Inc. (VRTX).
Novavax continues big surge on coronavirus vaccine federal aid
Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of
Companies that have positive and steady net margins and operating margins are often good investments because they can return a solid profit to investors.
According to the GuruFocus discounted cash flow calculator as of June 25, the following undervalued companies have a high margin of safety and have grown their margins over a 10-year period.
Cognizant Technology Solutions Corp.'s (CTSH) net margin and operating margin have grown 13.49% and 17.93% per annum, respectively, over the past 10 years.
According to the DCF calculator, the stock is undervalued with a 7.74% margin of safety at $53.85 per share. The
According to the GuruFocus All-in-One Screener, a Premium feature, as of June 9, the following guru-held companies are trading at a discount and have positive future earnings estimates from Morningstar analysts.
Shares of Alexion Pharmaceuticals Inc. (ALXN) were trading around $119.74 on Tuesday.
The developer and marketer of drugs has a GuruFocus profitability rating of 9 out of 10. Its earnings per share have climbed 82.50% over the past three years.
Analysts project a three-year to five-year earnings growth rate of 12.98%. The return on equity of 22.29% and return
Shares of Alexion Pharmaceuticals Inc. (ALXN) were up fractionally on Tuesday after activist investment frim Elliot Advisors again called for a company sale. In a letter to chairman David Brennan, the hedge fund said Alexion should go out and look for a buyer because mismanagement has cratered shareholder value.
In the past five years, the price of the Boston-based biotech has slid more than 45% to about $104. It appears the last straw for Elliott was the company’s acquisition of Portola Pharmaceuticals Inc. (PTLA). When the deal was announced last week, Elliott noted that Alexion’s market value was shaved by
The guru increased the Alexion Pharmaceuticals Inc. (ALXN) position by 2.59% in the fourth quarter and then boosted it 127.04% in the first quarter.
The company, which develops drugs for rare, life-threatening medical conditions, has a market cap of $21.51 billion. Its revenue of $4.99 billion has grown 15% over the last five years.
In light of countries around the world investing in vaccines to curb future waves of the coronavirus, five pharmaceutical companies with high financial strength and profitability are Alexion Pharmaceuticals Inc. (ALXN), Biogen Inc. (BIIB), Johnson & Johnson (JNJ), Novo Nordisk A/S (NVO) and Bio-Techne Corp. (TECH).
According to John Hopkins University statistics, global cases have eclipsed 2 million as of Thursday, with nearly 640,000 cases in the U.S. The World Health Organization added that the coming weeks are “critical” as cases in Europe reach nearly 1 million.
Companies around the globe share vaccine plans
U.K.-based GlaxoSmithKline PLC
You can increase the effectiveness of your search for value opportunities if you choose fairly priced or undervalued stocks.
This is what Benjamin Graham, the father of value investing, recommended as a shortcut: multiply the stock’s price-earnings ratio by its price-book ratio to build what is known as the "Graham blended multiplier," then choose those stocks whose blended multiplier is less than 22.5.
Thus, the following three stocks may grant value opportunities as their Graham blended multiplier stands below 22.5.
KKR & Co Inc
The first stock that meets the above-listed criteria is KKR & Co Inc (KKR).
According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have grown their book value per share over the past decade through April 2.
Book value per share is calculated as total equity minus preferred stock, divided by shares outstanding. Theoretically, it is what shareholders will receive if a company is liquidated. Total equity is a balance sheet item and is equal to total assets minus total liabilities.
Since the book value per share may not reflect the company’s true value, some investors check the tangible book value to confirm their investment ideas.
As of Monday, the GuruFocus All-in-One Screener, a Premium feature, found that the following stocks have low price-earnings ratios and have been bought by gurus. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.
With a market cap of $11.08 billion, Bio-Rad Laboratories Inc. (BIO) has a price-earnings ratio of 6.43. According to the DCF calculator, the stock has a fair value of $820 while trading at $374. The stock has gained 21% over the last 12 months and is now 9.3%
Segalas exited his position in Chinese conglomerate Tencent Holdings Ltd. (HKSE:00700). The portfolio was impacted by -2.08%.
The company, which provides solutions for enterprise resource planning, database management and business intelligence, has a market cap of $167.69 billion and an enterprise value of $179.55 billion.
GuruFocus gives the company a
The guru increased the Accuray Inc. (ARAY) position by 98.44% in the second quarter and then added 56.02% in the third quarter. The stock has a weight of 0.01% in the portfolio.
The company which develops solutions for radiation therapy, has a market cap of $271.71 million. Its revenue of $412 million has fallen 0.60% per annum over the last
Managed by Jason Kritzer and Samantha Pandolfi, the Boston-based fund invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.
Based on these criteria, the fund opened positions in Alexion Pharmaceuticals Inc. (ALXN), Fisher & Paykel Healthcare Corp. Ltd. (NZSE:FPH), Alnylam Pharmaceuticals Inc. (ALNY), Argenx SE (ARGX) and Sarepta Therapeutics Ltd. (SRPT) during the quarter.
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio), which provides advanced, customized solutions to forward-thinking investors, sold shares of the following stocks during the third quarter.
The fund closed its Aetna Inc. (AET) holding. The trade had an impact of -1.82% on the portfolio.
The company, which offers health insurance products and related services, has a market cap of $69.64 billion and an enterprise value of $68.65 billion.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. The return on equity of 22.01% and
Adecoagro SA (AGRO)
In the second quarter, the guru boosted his position by 89.53% and added another 26.8% in the third quarter.
With a market cap of $812.39 million, the company operates dairies and is involved in other agricultural endeavors. Its revenue of $885.78 million has grown 11.80% over the last five years.
The U.S. stock market fell today, with the Dow Jones down more than 200 points. According to the Wall Street Journal, President Trump will restrict Chinese companies' investment in the tech sector, but the news will be announced later in the week.
Shares of Xerium Technologies Inc. (XRM) jumped in Monday trading on news that the company will be acquired by Andritz AG for $13.50 per share, representing more than 100% from Friday's closing price.
With the deal, valued at approximately $833 million,Andritz will strengthen its position in the paper industry.
"We are very excited about this coming together with